ENGLISH
ÑÇÖÞ±ØÓ®×ÊѶ
News
ÑÇÖÞ±ØÓ®Ò½Ò©ºÍͬԴ¿µÒ½Ò©¸æ¿¢Ò»Ïî¶à°Ðµã¼¤Ã¸ÒÖÖƼÁ´óÖлªÇøȨÒæÉúÒâ
Ðû²¼Ê±¼ä:
2020-09-02
2020Äê8ÔÂ31ÈÕ£¬£¬ÑÇÖÞ±ØÓ®£¨ÒÔϼò³Æ¡°ÑÇÖÞ±ØÓ®Ò½Ò©¡±£©ÓëÕã½Í¬Ô´¿µÒ½Ò©¹É·ÝÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°Í¬Ô´¿µÒ½Ò©¡±£©¡ª¡ªÒ»¼ÒרעÓÚÑз¢È«ÇòÁìÏÈС·Ö×Ó¿¹Ö×ÁöÐÂÒ©µÄÉúÎïÊÖÒÕ¹«Ë¾£¬£¬¾ÍͬԴ¿µÒ½Ò©µÄTY-2136bÇ©ÊðÁËÒ»ÏîÔÚ´óÖлªÇøµÄרÀûתÈü°ÊÖÒÕ¶ÀÍÌÔÊÐíÐÒé¡£¡£¡£
TY-2136bÊÇͬԴ¿µÒ½Ò©×ÔÖ÷Ñз¢µÄÒ»¿î´¦ÓÚPCC£¨ÁÙ´²Ç°ºòÑ¡»¯ºÏÎ½×¶ÎµÄÐÂÒ»´úROS1/NTRK/ALK¶à°ÐµãС¹ãÆ×ÀÒ°±ËἤøÒÖÖƼÁ£¨TKI£©¡£¡£¡£ÁÙ´²Ç°Ñо¿Åú×¢£¬£¬TY-2136b¶ÔROS1/NTRK/ALK¶à¸ö°Ðµã¾ùÏÔʾ³öÓÅÒìµÄÁÆЧ£¬£¬Í¬Ê±»¹ÄÜÓÐÓÃÒÖÖÆÄÍÒ©»ùÒòÍ»±ä£¬£¬ÓÐÓýâ¾öÖî¶àδ֪×ãÁÙ´²ÐèÇ󡣡£¡£
ÑÇÖÞ±ØÓ®Ò½Ò©Ö´Ðжʼæ×ܲÃÌÆÑô¸ÕÏÈÉúÌåÏÖ£º¡°´Ë´ÎÓëͬԴ¿µÒ½Ò©µÄÏàÖú¿ÉÒÔ³ä·ÖÑéÕ¹¸÷×ÔµÄÓÅÊÆ£¬£¬¼ÓËÙÐÂÒ©Ñз¢ÉÏÊУ¬£¬½øÒ»²½Ôö²¹ÑÇÖÞ±ØÓ®Ò½Ò©µÄÖ×Áö²úÆ·¹ÜÏß¡£¡£¡£ºã¾ÃÒÔÀ´£¬£¬ÑÇÖÞ±ØÓ®Ò»Ö±ÖÂÁ¦ÓÚÖ×ÁöÁ¢ÒìÒ©µÄ¿ª·¢£¬£¬ÖйúµÄÖ×Áö»¼ÕßÈÔÈ»ÐèÒª¸ü¶à¸üºÃµÄÖÎÁÆÒ©Î£¬»ùÓÚÏÖÔÚTY-2136bÓÅÒìµÄÁÙ´²Ç°Êý¾Ý£¬£¬ÎÒÃÇÏàÐÅδÀ´¸Ã²úÆ·ÉÏÊкóÒ»¶¨»áÔ츣ÖйúµÄÖ×Áö»¼Õß¡£¡£¡£¡£¡£¡±
ͬԴ¿µÒ½Ò©¶Ê³¤¼æÊ×ϯִÐйÙÎâÔ¥Éú²©Ê¿ÌåÏÖ£º¡°ºÜÐË·ÜÓÐʱ»úÓëÑÇÖÞ±ØÓ®Ò½Ò©ÏàÖú£¬£¬¼ÓËÙÍƽøTY-2136bµÄÑз¢¡¢¡¢ÁÙ´²¿ª·¢ºÍÉÌÒµ»¯¡£¡£¡£Ö»¹ÜͬԴ¿µ³ÉÁ¢Ê±¼ä²»¾Ã£¬£¬¿ÉÊÇÓµÓÐÇ¿Ê¢µÄÑз¢ÄÜÁ¦¡£¡£¡£´Ë´ÎÀÖ³ÉÓëÑÇÖÞ±ØÓ®Ò½Ò©ÏàÖú£¬£¬Ò²ÊÇÎÒÃÇÍŶÓÑз¢ÄÜÁ¦µÄÕ¹ÏÖ¡£¡£¡£¡£¡£¡±Í¬Ô´¿µÒ½Ò©Ê×ϯ¿Æѧ¹ÙÀî¾û²©Ê¿ÌåÏÖ£º¡°Í¬Ô´¿µµÄÁ¢Ïî±ê×¼¾ÍÊǽâ¾öδ֪×ãÁÙ´²ÐèÇ󣬣¬²¢ÇÒ×öͬÀàÒ©ÎïµÄBest-in-Class¡£¡£¡£ÁÙ´²Ç°Êý¾ÝÅú×¢£¬£¬TY-2136b ¶ÔROS1/NTRK/ALKµÄÖ÷ÒªÄÍÒ©Í»±ä¾ùÏÔʾÁËÀàËÆ»ò¸üºÃµÄÒÖÖÆЧ¹û¡£¡£¡£Í¬Ê±£¬£¬TY-2136b¾ßÓÐÒ»¶¨µÄ´©Í¸ÑªÄÔÆÁÕÏÄÜÁ¦£¬£¬ ¶ÔÄÔתÒÆ»¼Õß¾ßÓÐDZÔÚÓÅÊÆ¡£¡£¡£
¾Ý±¨µÀ£¬£¬·Î°©ÊÇÌìÏ°©Ö¢éæÃüµÄÖ÷ÒªÔÒòÖ®Ò»¡£¡£¡£ÆäÖÐÔ¼85%Ϊ·ÇСϸ°û·Î°©»¼Õߣ¨NSCLC£©[1]£¬£¬2015ÄêÖйú¶ñÐÔÖ×ÁöÊ¢ÐÐÇéÐÎÆÊÎöÏÔʾ£¬£¬Öйú·Î°©»¼ÕßÿÄêÐÂÔöÔ¼78.7ÍòÈË[2]¡£¡£¡£°´Ö°©Çý¶¯»ùÒò·ÖÀ࣬£¬ROS1ÑôÐÔÕ¼NSCLC»¼ÕßÊýÄ¿Ô¼2%£¬£¬ÆäÖÐÁè¼Ý°ëÊý»¼ÕßÔÚ½ÓÊÜÏÖÓаÐÏòÒ©ÎïÖÎÁƺó»á±¬·¢G2032R¡¢¡¢D2033NµÈÄÍÒ©ÐÔÍ»±ä[3]£»NTRK»ùÒòÈÚºÏÍ»±ä¶øµ¼Öµİ©Ö¢»¼ÕßÊýÄ¿Ô¼Õ¼NSCLC»¼ÕßÊýÄ¿µÄ0.5-1% [4]£¬£¬±ðµÄÓɸûùÒòÈںϻ¹¿ÉÒýÆð¶àÖÖ°©Ö¢°üÀ¨À»Î²°©¡¢¡¢ÈéÏÙ°©¡¢¡¢µ¨¹Ü°©¡¢¡¢½áÖ±³¦°©¡¢¡¢Î¸³¦µÀ¼äÖÊÁö£¨GIST£©ºÍÐí¶àÆäËû¹²17ÖÖʵÌåÁö¡£¡£¡£ALKÑôÐÔÔ¼Õ¼NSCLC»¼ÕßÊýÄ¿µÄ5-8%[5]£¬£¬¾ALKÒÖÖƼÁÖÎÁÆ£¬£¬ÓÈÆäÊǶþ´úALKÒÖÖƼÁÖÎÁƺ󣬣¬»á±¬·¢´ó×ÚG1202RÄÍÒ©Í»±ä¡£¡£¡£
¹ØÓÚͬԴ¿µÒ½Ò©
ͬԴ¿µÒ½Ò©ÊÇÒ»¼Òפ×ãÖйú¡¢¡¢ÃæÏò¹ú¼ÊµÄÁ¢ÒìÐÍÉúÎïÒ½Ò©¸ß¿Æ¼¼¹«Ë¾£¬£¬ÔÚÕ㽺þÖݳ¤Ð˾¼Ã¿ª·¢ÇøµÄ´óÁ¦Ö§³ÖÏ£¬£¬ÓÚ³¤ÐËÉúÃü¿Æѧ԰½¨ÉèÁË3000m2ÐÂÒ©Ñз¢ÖÐÐÄ£¬£¬ÓµÓÐÈ«ÇòÒ»Á÷µÄÐÂÒ©Ñз¢ÊµÑéÊÒÒÔ¼°ÎÄÏ×Ç鱨ÖÐÐÄ¡£¡£¡£ÔÚÉϺ£½¨ÉèÁËÁÙ´²Ò½Ñ§²¿ºÍÉÌÎñÍØÕ¹²¿¡£¡£¡£
¹ØÓÚÑÇÖÞ±ØÓ®Ò½Ò©
ÑÇÖÞ±ØÓ®Ò½Ò©£¨001513.SZ , 1513.HK£©½¨ÉèÓÚ1985Ä꣬£¬×¢²á×ÊԴΪ9.57ÒÚÔª£¬£¬ÊǼ¯Ò½Ò©Ñз¢¡¢¡¢Éú²ú¡¢¡¢ÏúÊÛΪһÌåµÄ×ÛºÏÒ½Ò©¼¯ÍŹ«Ë¾£¬£¬ÏÖÓÐÔ±¹¤8000ÓàÈË¡£¡£¡£ÑÇÖÞ±ØÓ®ÖÂÁ¦ÓÚÖÊÁÏÒ©¡¢¡¢Ð¡·Ö×ÓÒ©Îï¡¢¡¢ÉúÎïÒ©¡¢¡¢ÒÔ¼°Õï¶ÏÊÔ¼ÁµÄÑз¢¡¢¡¢Éú²ú¼°ÏúÊÛ£¬£¬ÆäÖصãÖÎÁÆÁìÓòº¸Ç¿¹Ö×Áö¡¢¡¢ÉúÖ³ÄÚÉø͸¡¢¡¢Ïû»¯¡¢¡¢¿¹Ñ¬È¾¡¢¡¢¾«Éñ/Éñ¾¡¢¡¢ÄÚÉø͸µÈ¶à¸öÁìÓò¡£¡£¡£
²Î¿¼ÎÄÏ×£º
1.Herbst R S , Morgensztern D , Boshoff C . The biology and management of non-small cell lung cancer[J]. Nature, 2018, 553(7689):446-454.
2.Ö£ÈÙÊÙ, Ëï¿ÉÐÀ, ÕÅÍ·ÄÔ, µÈ. 2015ÄêÖйú¶ñÐÔÖ×ÁöÊ¢ÐÐÇéÐÎÆÊÎö [J] . ÖлªÖ×ÁöÔÓÖ¾,2019,41( 1 ): 19-28. DOI: 10.3760/cma.j.issn.0253-3766.2019.01.005
3.Gainor JF, Tseng D, Yoda S, et al. Patterns of Metastatic Spread and Mechanisms of Resistance to Crizotinib in ROS1-Positive Non-Small-Cell Lung Cancer. JCO Precision Oncology. 2017 ;2017. DOI: 10.1200/po.17.00063.
4.Ricciuti, B., et al., Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence. Med Oncol, 2017. 34(6): p. 105.
5.McCoach CE, Le AT, Gowan K, et al. Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res. 2018;24(14):3334-3347. doi:10.1158/1078-0432.CCR-17-2452
